• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vapotherm Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    9/19/24 12:35:46 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    vapo20240916_8k.htm
    false 0001253176 0001253176 2024-09-19 2024-09-19
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
     
    FORM 8-K
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): September 19, 2024
     

     
    Vapotherm, Inc.
     
    (Exact name of registrant as specified in its charter)
     

    Delaware
    001-38740
    46-2259298
    (State or other jurisdiction
    of incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
             
    100 Domain Drive
     
    Exeter, New Hampshire
     
    03833
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (603) 658-0011
     
    Not Applicable
    (Former name or former address, if changed since last report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange on which registered
    N/A
     
    N/A
     
    N/A
     
     
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     
     

     
     
    Item 5.07         Submission of Matters to a Vote of Security Holders.
     
    Vapotherm, Inc., a Delaware corporation (the “Company”), held a special meeting of stockholders on September 19, 2024 (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of Merger, dated as of June 17, 2024 (the “Merger Agreement”), by and among Veronica Holdings, LLC, a Delaware limited liability company (“Topco”), Veronica Intermediate Holdings, LLC, a Delaware limited liability company and wholly owned subsidiary of Topco (“Parent”), Veronica Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and the Company, pursuant to which, among other things, Merger Sub will merge with and into the Company (the “Merger”), and as a result of which the separate corporate existence of Merger Sub will cease, and the Company will continue as the surviving corporation of the Merger and as a direct, wholly owned subsidiary of Parent.
     
    As of the close of business on August 12, 2024, the record date for the Special Meeting (the “Record Date”), there were 6,244,935 shares of the Company’s common stock, par value $0.001 per share (the “Company Common Stock”), outstanding and entitled to vote at the Special Meeting. Each share of Company Common Stock was entitled to one vote. Stockholders holding an aggregate of 3,568,829 shares of Company Common Stock entitled to vote at the Special Meeting, representing 57.15% of the outstanding shares of Company Common Stock as of the Record Date, and which constituted a quorum thereof, were present in person or represented by proxy at the Special Meeting.
     
    At the Special Meeting, the following proposals were considered, each of which is described in more detail in the Company’s definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on August 15, 2024:
     
     
    1.
    To adopt the Merger Agreement by and among Topco, Parent, Merger Sub and the Company, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger (the “Merger Agreement Proposal”);
     
    2.
    To approve, on a non-binding basis, the compensation that may be paid or become payable to the Company’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”); and
     
    3.
    Any proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies to approve the Merger Agreement Proposal if there are insufficient votes to approve the Merger Agreement Proposal at the time of the Special Meeting (the “Adjournment Proposal”).
     
    The approval of the Merger Agreement Proposal required the affirmative vote of the holders of a majority of the shares of Company Common Stock outstanding as of the close of business on the Record Date. The approval of the Compensation Proposal, on a non-binding, advisory basis, required the affirmative vote of a majority of votes cast at the Special Meeting. The approval of the Adjournment Proposal required the affirmative vote of a majority of votes cast at the Special Meeting.
     
    Proposal No. 1: Merger Agreement Proposal.
     
    The stockholders approved the Merger Agreement Proposal by the following final voting results:
     
    Votes For
     
    Votes Against
     
    Abstain
     
    Broker Non-Votes
    3,503,337
     
    60,664
     
    4,828
     
    0
     
    Proposal No. 2: Compensation Proposal.
     
    The stockholders approved, on a non-binding basis, the Compensation Proposal by the following final voting results:
     
    Votes For
     
    Votes Against
     
    Abstain
     
    Broker Non-Votes
    3,480,625
     
    80,942
     
    7,262
     
    0
     
    Each of the Merger Agreement Proposal and the Compensation Proposal was approved by the required vote of the Company’s stockholders. As there were sufficient votes from the Company’s stockholders to approve the Merger Agreement, adjournment of the Special Meeting was unnecessary and the Adjournment Proposal was not presented to the Company’s stockholders.
     
    The completion of the Merger remains subject to the satisfaction of other closing conditions as set forth in the Merger Agreement.
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
     
         
    Vapotherm, Inc.
           
    Date:
    September 19, 2024
    By:
    /s/ James A. Lightman
         
    James A. Lightman
    Senior Vice President, General Counsel and Secretary
     
     
    Get the next $VAPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    SEC Filings

    View All

    SEC Form 15-12G filed by Vapotherm Inc.

    15-12G - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 11:32:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:03 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:04 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vapotherm Announces Closing of Merger

    EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

    9/20/24 10:33:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports Second Quarter 2024 Financial Results

    EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

    8/12/24 5:15:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

    EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

    6/17/24 6:55:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

    4/A - VAPOTHERM INC (0001253176) (Issuer)

    10/4/23 4:11:34 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 5:01:08 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:43:19 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:14:26 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vapotherm downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

    5/6/22 7:28:09 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

    4/7/22 7:25:32 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Piper Sandler reiterated coverage on Vapotherm with a new price target

    Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

    2/25/21 7:36:13 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Financials

    Live finance-specific insights

    View All

    Vapotherm To Report Second Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

    7/25/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

    5/3/23 4:10:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm To Report First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

    4/27/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    View All

    Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

    TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

    9/8/23 8:30:00 AM ET
    $IART
    $VAPO
    Medical/Dental Instruments
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/24/24 7:04:57 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/20/24 10:32:59 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vapotherm Inc.

    SC 13G - VAPOTHERM INC (0001253176) (Subject)

    7/18/24 7:24:17 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care